Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zimmer Biomet Holdings, Inc. (NYSE: ZBH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zimmer Biomet is a global medical technology company focused on musculoskeletal health and orthopedic implants, and its filings offer detailed insight into its operations, capital structure, risk factors and governance.
Through this page, you can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss Zimmer Biomet’s product categories such as knees, hips, sports medicine, extremities, trauma, craniomaxillofacial and thoracic (S.E.T.), and technology and data, bone cement and surgical. These reports typically include segment and geographic sales information, descriptions of the company’s digital and robotic technologies, and management’s discussion and analysis.
You will also find current reports on Form 8-K covering material events, including quarterly earnings releases, new debt issuances, revolving credit agreements, acquisitions such as the merger with Monogram Technologies Inc., and other significant corporate developments. Filings describing the company’s notes and bonds, including series listed on the New York Stock Exchange, provide detail on interest rates, maturities, covenants and redemption features.
Stock Titan enhances these documents with AI-powered summaries that explain key points in clear language, helping users navigate complex topics like non-GAAP financial measures, leverage covenants and transaction structures. The platform also surfaces insider and executive-related filings, such as those reporting departures or appointments of certain officers, so users can track governance changes. With real-time updates from EDGAR and AI-generated highlights, this page is a focused resource for analyzing Zimmer Biomet’s SEC reporting history and ongoing regulatory disclosures.
Zimmer Biomet Holdings executive Noor Jehanzeb reported the vesting and exercise of 6,626 restricted stock units (RSUs) into the same number of shares of common stock on April 1, 2026. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock.
To cover tax obligations on this vesting, 1,677 shares of common stock were withheld by the company at a value of $90.67 per share, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Jehanzeb directly holds 5,151 shares of common stock, which include 202 shares previously acquired under the Employee Stock Purchase Plan, and 13,249 RSUs that continue to vest, with one-third vesting on April 1, 2026 and the remaining RSUs vesting in two equal installments on April 1, 2027 and April 1, 2028.
Jafry Syed A. reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Syed A. Jafry received 182.421 phantom stock units as a compensation award. These units were granted under the Zimmer Biomet Deferred Compensation Plan for Non-Employee Directors and are convertible into an equal number of common shares on a 1-for-1 basis. Following this award, Jafry holds a total of 7,391.591 phantom stock units, which are to be settled in company common stock within sixty days after his service as a director ends.
Kolli Sreelakshmi reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Kolli Sreelakshmi received a grant of phantom stock units as director compensation. On March 31, 2026, she was awarded 175.404 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors, tied 1-for-1 to common stock. These units are to be settled in shares of company common stock within sixty days after she ceases serving as a director. Following this award and prior dividend reinvestments, she now holds a total of 5,769.994 phantom stock units, including 15.067 units accrued on January 30, 2026 through the plan’s dividend reinvestment provision.
Shapiro Louis reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Louis Shapiro received a grant of 154.356 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors. These units are a form of deferred equity-based compensation rather than a cash payment.
The award brings his total Phantom Stock Units to 2,661.254, each convertible into one share of common stock on a 1-for-1 basis. The units will be settled in company common stock within sixty days after his service as a director ends, and the total includes 6.544 units accrued on January 30, 2026 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Maria Teresa Hilado received a grant of phantom stock units as part of her non-employee director compensation. She acquired 378.873 phantom stock units tied on a 1-for-1 basis to common stock value, bringing her total phantom stock units to 11,684.719.
These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and will be settled in cash through ten annual installments starting within sixty days after the calendar year in which her board service ends. The total includes 30.381 units added earlier through the plan’s dividend reinvestment provision.
HIGGINS ARTHUR J reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Arthur J. Higgins received a grant of 308.711 Phantom Stock Units on March 31, 2026 under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is convertible on a 1-for-1 basis with common stock but is to be settled in cash.
The units are scheduled to be paid in ten annual installments, beginning within sixty days after the end of the calendar year in which Higgins’ service as a director ends. Following this award and prior accruals, including 99.385 units from dividend reinvestment on January 30, 2026, he holds 36,375.195 phantom stock units.
Kurdikar Devdatt reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Devdatt Kurdikar received a grant of 154.356 Phantom Stock Units, each tied 1-for-1 to common shares. These units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors at a stated price of $0.0000 per unit.
Following this award, Kurdikar holds a total of 1,928.847 Phantom Stock Units. The units, including 4.508 accrued through dividend reinvestment on January 30, 2026, are scheduled to be settled in shares of Zimmer Biomet common stock within sixty days after his service as a director ends.
HAGEMANN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. director Robert Hagemann reported receiving a grant of 308.711 Phantom Stock Units on March 31, 2026. These units are tied 1-for-1 to the company’s common stock value and increase his deferred balance to 31,982.841 units.
The units were accrued under Zimmer Biomet’s Deferred Compensation Plan for Non-Employee Directors and will be settled in cash in five annual installments after his board service ends. His balance also includes 87.178 phantom units added earlier under the plan’s dividend reinvestment provision.
Farrell Michael J. reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. director Michael J. Farrell reported an award of phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors. He received 420.97 phantom stock units tied on a 1-for-1 basis to common stock, bringing his total phantom stock holdings to 18,245.033 units.
The phantom stock units are cash-settled in a lump sum within sixty days after he ceases serving as a director. His total includes 48.381 phantom stock units accrued on January 30, 2026 through the plan’s dividend reinvestment provision.